These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38501355)

  • 61. Dimercaptosuccinic acid in combination with carbapenems against isogenic strains of Escherichia coli producing or not producing a metallo-β-lactamase in vitro and in murine peritonitis.
    Cheminet G; de Lastours V; Poirel L; Chau F; Peoc'h K; Massias L; Fantin B; Nordmann P
    J Antimicrob Chemother; 2020 Dec; 75(12):3593-3600. PubMed ID: 32790873
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Assessment of Chromosomal DNA Fragmentation by Quinolones in an Isogenic Collection of Escherichia coli with Defined Resistance Mechanisms.
    Rodríguez-Martínez JM; Santiso R; Machuca J; Bou G; Pascual Á; Fernández JL
    Microb Drug Resist; 2016 Jul; 22(5):354-9. PubMed ID: 26890225
    [TBL] [Abstract][Full Text] [Related]  

  • 63.
    Stewart AG; Cottrell K; Henderson A; Vemuri K; Bauer MJ; Paterson DL; Harris PNA
    Microbiol Spectr; 2021 Sep; 9(1):e0022621. PubMed ID: 34232101
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Evaluation of Antimicrobial Effects of a New Polymyxin Molecule (SPR741) When Tested in Combination with a Series of β-Lactam Agents Against a Challenge Set of Gram-Negative Pathogens.
    Mendes RE; Rhomberg PR; Lister T; Cotroneo N; Rubio A; Flamm RK
    Microb Drug Resist; 2020 Apr; 26(4):319-328. PubMed ID: 31596663
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cefmetazole as an Alternative to Carbapenems Against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Infections Based on In Vitro and In Vivo Pharmacokinetics/Pharmacodynamics Experiments.
    Takemura W; Tashiro S; Hayashi M; Igarashi Y; Liu X; Mizukami Y; Kojima N; Morita T; Enoki Y; Taguchi K; Yokoyama Y; Nakamura T; Matsumoto K
    Pharm Res; 2021 Nov; 38(11):1839-1846. PubMed ID: 34853981
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Fluoroquinolone resistance mechanisms in urinary tract pathogenic Escherichia coli isolated during rapidly increasing fluoroquinolone consumption in a low-use country.
    Christiansen N; Nielsen L; Jakobsen L; Stegger M; Hansen LH; Frimodt-Møller N
    Microb Drug Resist; 2011 Sep; 17(3):395-406. PubMed ID: 21668371
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Emergence of imipenem resistance in clinical Escherichia coli during therapy.
    Oteo J; Delgado-Iribarren A; Vega D; Bautista V; Rodríguez MC; Velasco M; Saavedra JM; Pérez-Vázquez M; García-Cobos S; Martínez-Martínez L; Campos J
    Int J Antimicrob Agents; 2008 Dec; 32(6):534-7. PubMed ID: 18775649
    [TBL] [Abstract][Full Text] [Related]  

  • 68. In vitro development and analysis of Escherichia coli and Shigella boydii azithromycin-resistant mutants.
    Gomes C; Pons MJ; Magallon-Tejada A; Durand D; Lluque A; Mosquito S; Riveros M; Mercado E; Prada A; Ochoa TJ; Ruiz J
    Microb Drug Resist; 2013 Apr; 19(2):88-93. PubMed ID: 23176550
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Role of host and bacterial virulence factors in Escherichia coli spontaneous bacterial peritonitis.
    Cereto F; Herranz X; Moreno E; Andreu A; Vergara M; Fontanals D; Roget M; Simó M; González A; Prats G; Genescà J
    Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):924-9. PubMed ID: 18794608
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Rapid emergence of high-level tigecycline resistance in Escherichia coli strains harbouring blaNDM-5 in vivo.
    Li X; Mu X; Yang Y; Hua X; Yang Q; Wang N; Du X; Ruan Z; Shen X; Yu Y
    Int J Antimicrob Agents; 2016 Apr; 47(4):324-7. PubMed ID: 26944192
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Does mutation in gyrA and/or parC or efflux pump expression play the main role in fluoroquinolone resistance in Escherichia coli urinary tract infections?: A statistical analysis study.
    Shigemura K; Tanaka K; Yamamichi F; Shirakawa T; Miyake H; Fujisawa M
    Int J Antimicrob Agents; 2012 Dec; 40(6):516-20. PubMed ID: 23068598
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Susceptibility of Escherichia coli from community-acquired urinary tract infection to fosfomycin, nitrofurantoin, and temocillin in Korea.
    Seo MR; Kim SJ; Kim Y; Kim J; Choi TY; Kang JO; Wie SH; Ki M; Cho YK; Lim SK; Lee JS; Kwon KT; Lee H; Cheong HJ; Park DW; Ryu SY; Chung MH; Pai H
    J Korean Med Sci; 2014 Aug; 29(8):1178-81. PubMed ID: 25120333
    [TBL] [Abstract][Full Text] [Related]  

  • 73. In vitro activity of beta-lactam antibiotics against CTX-M-producing Escherichia coli.
    Tärnberg M; Ostholm-Balkhed A; Monstein HJ; Hällgren A; Hanberger H; Nilsson LE
    Eur J Clin Microbiol Infect Dis; 2011 Aug; 30(8):981-7. PubMed ID: 21298459
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Unravelling mechanisms of nitrofurantoin resistance and epidemiological characteristics among Escherichia coli clinical isolates.
    Zhang X; Zhang Y; Wang F; Wang C; Chen L; Liu H; Lu H; Wen H; Zhou T
    Int J Antimicrob Agents; 2018 Aug; 52(2):226-232. PubMed ID: 29753133
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Molecular Characterization of Multidrug-Resistant
    Sadeghi M
    Microb Drug Resist; 2019 Nov; 25(9):1287-1296. PubMed ID: 31216231
    [No Abstract]   [Full Text] [Related]  

  • 76. Resurrecting Old β-Lactams: Potent Inhibitory Activity of Temocillin against Multidrug-Resistant
    Zeiser ET; Becka SA; Barnes MD; Taracila MA; LiPuma JJ; Papp-Wallace KM
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718248
    [No Abstract]   [Full Text] [Related]  

  • 77. Comparative in vitro activity of temocillin and other antimicrobial agents against Enterobacteriaceae isolated from patients admitted to five Belgian hospitals.
    Vanhoof R; Bérin C; Carpentier M; Fagnart O; Glupczynski Y; Mans I; Nyssen HJ; Surmont I; Van Nimmen L
    Acta Clin Belg; 2001; 56(6):354-9. PubMed ID: 11881320
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Characterization of Escherichia coli pathogenicity and drug resistance in yolk peritonitis.
    Li Q; Fang W; Chen S; Li G; Jiang C; Zhuang Y; Li L; Liu P; Guo X; Hu G; Liu P; Gao X
    Poult Sci; 2024 Jul; 103(7):103814. PubMed ID: 38718538
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prevalence of quinolone resistance mechanisms and associations to minimum inhibitory concentrations in quinolone-resistant Escherichia coli isolated from humans and swine in Denmark.
    Cavaco LM; Frimodt-Møller N; Hasman H; Guardabassi L; Nielsen L; Aarestrup FM
    Microb Drug Resist; 2008 Jun; 14(2):163-9. PubMed ID: 18500921
    [TBL] [Abstract][Full Text] [Related]  

  • 80. In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Escherichia coli.
    Monogue ML; Nicolau DP
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7527-7529. PubMed ID: 27799205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.